A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism
Identifieur interne :
003292 ( PascalFrancis/Corpus );
précédent :
003291;
suivant :
003293
A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism
Auteurs : A. Negrotti ;
S. CalzettiSource :
-
Movement disorders [ 0885-3185 ] ; 1997.
RBID : Pascal:97-0142930
Descripteurs français
- Pascal (Inist)
- Parkinsonisme,
Cinnarizine,
Antihistaminique,
Antiémétique,
Flunarizine,
Vasodilatateur,
Antagoniste calcium,
Antiallergique,
Toxicité,
Pronostic,
Vieillard,
Antagoniste,
Récepteur histaminergique H1,
Pipérazine dérivé,
Anticonvulsivant,
Etude longitudinale,
Long terme.
English descriptors
- KwdEn :
- Antagonist,
Antiallergic,
Anticonvulsant,
Antiemetic,
Antihistaminic,
Calcium antagonist,
Cinnarizine,
Elderly,
Flunarizine,
Follow up study,
H1 receptor,
Long term,
Parkinsonism,
Piperazine derivatives,
Prognosis,
Toxicity,
Vasodilator agent.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 12 |
---|
A06 | | | | @2 1 |
---|
A08 | 01 | 1 | ENG | @1 A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism |
---|
A11 | 01 | 1 | | @1 NEGROTTI (A.) |
---|
A11 | 02 | 1 | | @1 CALZETTI (S.) |
---|
A14 | 01 | | | @1 Istituto di Neurologia, Università di Parma @2 Parma @3 ITA @Z 1 aut. @Z 2 aut. |
---|
A20 | | | | @1 107-110 |
---|
A21 | | | | @1 1997 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000062292810170 |
---|
A44 | | | | @0 0000 @1 © 1997 INIST-CNRS. All rights reserved. |
---|
A45 | | | | @0 11 ref. |
---|
A47 | 01 | 1 | | @0 97-0142930 |
---|
A60 | | | | @1 P @3 CC |
---|
A61 | | | | @0 A |
---|
A64 | 01 | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C02 | 01 | X | | @0 002B02U01 |
---|
C03 | 01 | X | FRE | @0 Parkinsonisme @2 NM @5 01 |
---|
C03 | 01 | X | ENG | @0 Parkinsonism @2 NM @5 01 |
---|
C03 | 01 | X | SPA | @0 Parkinson síndrome @2 NM @5 01 |
---|
C03 | 02 | X | FRE | @0 Cinnarizine @2 NK @2 FR @5 04 |
---|
C03 | 02 | X | ENG | @0 Cinnarizine @2 NK @2 FR @5 04 |
---|
C03 | 02 | X | SPA | @0 Cinarizina @2 NK @2 FR @5 04 |
---|
C03 | 03 | X | FRE | @0 Antihistaminique @5 05 |
---|
C03 | 03 | X | ENG | @0 Antihistaminic @5 05 |
---|
C03 | 03 | X | SPA | @0 Antihistamínico @5 05 |
---|
C03 | 04 | X | FRE | @0 Antiémétique @5 06 |
---|
C03 | 04 | X | ENG | @0 Antiemetic @5 06 |
---|
C03 | 04 | X | SPA | @0 Antiemético @5 06 |
---|
C03 | 05 | X | FRE | @0 Flunarizine @2 NK @2 FR @5 07 |
---|
C03 | 05 | X | ENG | @0 Flunarizine @2 NK @2 FR @5 07 |
---|
C03 | 05 | X | SPA | @0 Flunarizina @2 NK @2 FR @5 07 |
---|
C03 | 06 | X | FRE | @0 Vasodilatateur @5 08 |
---|
C03 | 06 | X | ENG | @0 Vasodilator agent @5 08 |
---|
C03 | 06 | X | SPA | @0 Vasodilatador @5 08 |
---|
C03 | 07 | X | FRE | @0 Antagoniste calcium @5 09 |
---|
C03 | 07 | X | ENG | @0 Calcium antagonist @5 09 |
---|
C03 | 07 | X | SPA | @0 Antagonista calcio @5 09 |
---|
C03 | 08 | X | FRE | @0 Antiallergique @5 16 |
---|
C03 | 08 | X | ENG | @0 Antiallergic @5 16 |
---|
C03 | 08 | X | SPA | @0 Antialérgico @5 16 |
---|
C03 | 09 | X | FRE | @0 Toxicité @5 17 |
---|
C03 | 09 | X | ENG | @0 Toxicity @5 17 |
---|
C03 | 09 | X | GER | @0 Giftigkeit @5 17 |
---|
C03 | 09 | X | SPA | @0 Toxicidad @5 17 |
---|
C03 | 10 | X | FRE | @0 Pronostic @5 18 |
---|
C03 | 10 | X | ENG | @0 Prognosis @5 18 |
---|
C03 | 10 | X | SPA | @0 Pronóstico @5 18 |
---|
C03 | 11 | X | FRE | @0 Vieillard @5 20 |
---|
C03 | 11 | X | ENG | @0 Elderly @5 20 |
---|
C03 | 11 | X | SPA | @0 Anciano @5 20 |
---|
C03 | 12 | X | FRE | @0 Antagoniste @5 23 |
---|
C03 | 12 | X | ENG | @0 Antagonist @5 23 |
---|
C03 | 12 | X | SPA | @0 Antagonista @5 23 |
---|
C03 | 13 | X | FRE | @0 Récepteur histaminergique H1 @5 24 |
---|
C03 | 13 | X | ENG | @0 H1 receptor @5 24 |
---|
C03 | 13 | X | SPA | @0 Receptor histaminérgico H1 @5 24 |
---|
C03 | 14 | X | FRE | @0 Pipérazine dérivé @2 FR @5 29 |
---|
C03 | 14 | X | ENG | @0 Piperazine derivatives @2 FR @5 29 |
---|
C03 | 14 | X | SPA | @0 Piperazina derivado @2 FR @5 29 |
---|
C03 | 15 | X | FRE | @0 Anticonvulsivant @5 35 |
---|
C03 | 15 | X | ENG | @0 Anticonvulsant @5 35 |
---|
C03 | 15 | X | SPA | @0 Anticonvulsivante @5 35 |
---|
C03 | 16 | X | FRE | @0 Etude longitudinale @5 36 |
---|
C03 | 16 | X | ENG | @0 Follow up study @5 36 |
---|
C03 | 16 | X | SPA | @0 Estudio longitudinal @5 36 |
---|
C03 | 17 | X | FRE | @0 Long terme @5 77 |
---|
C03 | 17 | X | ENG | @0 Long term @5 77 |
---|
C03 | 17 | X | SPA | @0 Largo plazo @5 77 |
---|
C07 | 01 | X | FRE | @0 Homme |
---|
C07 | 01 | X | ENG | @0 Human |
---|
C07 | 01 | X | SPA | @0 Hombre |
---|
C07 | 02 | X | FRE | @0 Système nerveux pathologie @5 37 |
---|
C07 | 02 | X | ENG | @0 Nervous system diseases @5 37 |
---|
C07 | 02 | X | SPA | @0 Sistema nervioso patología @5 37 |
---|
C07 | 03 | X | FRE | @0 Extrapyramidal syndrome @5 38 |
---|
C07 | 03 | X | ENG | @0 Extrapyramidal syndrome @5 38 |
---|
C07 | 03 | X | SPA | @0 Extrapiramidal síndrome @5 38 |
---|
N21 | | | | @1 062 |
---|
|
Format Inist (serveur)
NO : | PASCAL 97-0142930 INIST |
ET : | A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism |
AU : | NEGROTTI (A.); CALZETTI (S.) |
AF : | Istituto di Neurologia, Università di Parma/Parma/Italie (1 aut., 2 aut.) |
DT : | Publication en série; Courte communication, note brève; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 1; Pp. 107-110; Bibl. 11 ref. |
LA : | Anglais |
CC : | 002B02U01 |
FD : | Parkinsonisme; Cinnarizine; Antihistaminique; Antiémétique; Flunarizine; Vasodilatateur; Antagoniste calcium; Antiallergique; Toxicité; Pronostic; Vieillard; Antagoniste; Récepteur histaminergique H1; Pipérazine dérivé; Anticonvulsivant; Etude longitudinale; Long terme |
FG : | Homme; Système nerveux pathologie; Extrapyramidal syndrome |
ED : | Parkinsonism; Cinnarizine; Antihistaminic; Antiemetic; Flunarizine; Vasodilator agent; Calcium antagonist; Antiallergic; Toxicity; Prognosis; Elderly; Antagonist; H1 receptor; Piperazine derivatives; Anticonvulsant; Follow up study; Long term |
EG : | Human; Nervous system diseases; Extrapyramidal syndrome |
GD : | Giftigkeit |
SD : | Parkinson síndrome; Cinarizina; Antihistamínico; Antiemético; Flunarizina; Vasodilatador; Antagonista calcio; Antialérgico; Toxicidad; Pronóstico; Anciano; Antagonista; Receptor histaminérgico H1; Piperazina derivado; Anticonvulsivante; Estudio longitudinal; Largo plazo |
LO : | INIST-20953.354000062292810170 |
ID : | 97-0142930 |
Links to Exploration step
Pascal:97-0142930
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism</title>
<author><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
<affiliation><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università di Parma</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Calzetti, S" sort="Calzetti, S" uniqKey="Calzetti S" first="S." last="Calzetti">S. Calzetti</name>
<affiliation><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università di Parma</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">97-0142930</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 97-0142930 INIST</idno>
<idno type="RBID">Pascal:97-0142930</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003292</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism</title>
<author><name sortKey="Negrotti, A" sort="Negrotti, A" uniqKey="Negrotti A" first="A." last="Negrotti">A. Negrotti</name>
<affiliation><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università di Parma</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Calzetti, S" sort="Calzetti, S" uniqKey="Calzetti S" first="S." last="Calzetti">S. Calzetti</name>
<affiliation><inist:fA14 i1="01"><s1>Istituto di Neurologia, Università di Parma</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antagonist</term>
<term>Antiallergic</term>
<term>Anticonvulsant</term>
<term>Antiemetic</term>
<term>Antihistaminic</term>
<term>Calcium antagonist</term>
<term>Cinnarizine</term>
<term>Elderly</term>
<term>Flunarizine</term>
<term>Follow up study</term>
<term>H1 receptor</term>
<term>Long term</term>
<term>Parkinsonism</term>
<term>Piperazine derivatives</term>
<term>Prognosis</term>
<term>Toxicity</term>
<term>Vasodilator agent</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Cinnarizine</term>
<term>Antihistaminique</term>
<term>Antiémétique</term>
<term>Flunarizine</term>
<term>Vasodilatateur</term>
<term>Antagoniste calcium</term>
<term>Antiallergique</term>
<term>Toxicité</term>
<term>Pronostic</term>
<term>Vieillard</term>
<term>Antagoniste</term>
<term>Récepteur histaminergique H1</term>
<term>Pipérazine dérivé</term>
<term>Anticonvulsivant</term>
<term>Etude longitudinale</term>
<term>Long terme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA08 i1="01" i2="1" l="ENG"><s1>A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NEGROTTI (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CALZETTI (S.)</s1>
</fA11>
<fA14 i1="01"><s1>Istituto di Neurologia, Università di Parma</s1>
<s2>Parma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>107-110</s1>
</fA20>
<fA21><s1>1997</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000062292810170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1997 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>11 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>97-0142930</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cinnarizine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cinnarizine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cinarizina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antihistaminique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antihistaminic</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antihistamínico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiémétique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiemetic</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiemético</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Flunarizine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Flunarizine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Flunarizina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vasodilatateur</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Vasodilator agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vasodilatador</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antagoniste calcium</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Calcium antagonist</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antagonista calcio</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Antiallergique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Antiallergic</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Antialérgico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="GER"><s0>Giftigkeit</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Vieillard</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Elderly</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Anciano</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Récepteur histaminergique H1</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>H1 receptor</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Receptor histaminérgico H1</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Pipérazine dérivé</s0>
<s2>FR</s2>
<s5>29</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Piperazine derivatives</s0>
<s2>FR</s2>
<s5>29</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Piperazina derivado</s0>
<s2>FR</s2>
<s5>29</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Anticonvulsivant</s0>
<s5>35</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Anticonvulsant</s0>
<s5>35</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Anticonvulsivante</s0>
<s5>35</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Etude longitudinale</s0>
<s5>36</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Follow up study</s0>
<s5>36</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Estudio longitudinal</s0>
<s5>36</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Long terme</s0>
<s5>77</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Long term</s0>
<s5>77</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>77</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fN21><s1>062</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 97-0142930 INIST</NO>
<ET>A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism</ET>
<AU>NEGROTTI (A.); CALZETTI (S.)</AU>
<AF>Istituto di Neurologia, Università di Parma/Parma/Italie (1 aut., 2 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 1; Pp. 107-110; Bibl. 11 ref.</SO>
<LA>Anglais</LA>
<CC>002B02U01</CC>
<FD>Parkinsonisme; Cinnarizine; Antihistaminique; Antiémétique; Flunarizine; Vasodilatateur; Antagoniste calcium; Antiallergique; Toxicité; Pronostic; Vieillard; Antagoniste; Récepteur histaminergique H1; Pipérazine dérivé; Anticonvulsivant; Etude longitudinale; Long terme</FD>
<FG>Homme; Système nerveux pathologie; Extrapyramidal syndrome</FG>
<ED>Parkinsonism; Cinnarizine; Antihistaminic; Antiemetic; Flunarizine; Vasodilator agent; Calcium antagonist; Antiallergic; Toxicity; Prognosis; Elderly; Antagonist; H1 receptor; Piperazine derivatives; Anticonvulsant; Follow up study; Long term</ED>
<EG>Human; Nervous system diseases; Extrapyramidal syndrome</EG>
<GD>Giftigkeit</GD>
<SD>Parkinson síndrome; Cinarizina; Antihistamínico; Antiemético; Flunarizina; Vasodilatador; Antagonista calcio; Antialérgico; Toxicidad; Pronóstico; Anciano; Antagonista; Receptor histaminérgico H1; Piperazina derivado; Anticonvulsivante; Estudio longitudinal; Largo plazo</SD>
<LO>INIST-20953.354000062292810170</LO>
<ID>97-0142930</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003292 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003292 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:97-0142930
|texte= A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism
}}
| This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 | ![](Common/icons/LogoDilib.gif) |